Solanova’s Nexrutine® Recognized By Consumer Health Digest

Today, Next Pharmaceuticals and Solanova revealed that Solonova’s Nexrutine®, was declared one of America’s Top 10 Pain Relievers by Consumer Health Digest. The health experts at the publication reviewed over 75 natural pain relief products currently available. Their rigorous assessment included review of the following product attributes: safety; joint and muscle pain relief; anti-inflammatory action; and support for healthy joints and connective tissue. “We’re very excited about the recognition that Consumer Health Digest has given Nexrutine®, said Garrison. “We have known that it is one of the best natural anti-inflammatory products on the market. This recognition is very validating and it helps get the word out to the people who need it.”

According to Mark Andersen, VP of Marketing for Solanova, “We are very pleased to receive a Safety rating of 5 out of 5 from Consumer Health Digest. But, frankly, we expected nothing less given the clinical data on Nexrutine proving how safe and effective it is.”

Solanova, “The Heart Health Company”, is a nutritional supplement company with the singular objective of helping optimize health and well-being utilizing the resources of nature. Founded over ten years ago in Northern California, Solanova is backed by millions of dollars invested in research and manufacturing. For more information go to

Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients such as Relora®, Nexrutine®, Seditol® and Citri-Z™ to food, beverage, and dietary supplement companies seeking differentiation and a marketing edge with their healthy living products. For more information log onto

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.